Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Harun M. Patel, Matin Shaikh, Iqrar Ahmad, Deepak Lokwani & Sanjay J. Surana. (2021) BREED based de novo hybridization approach: generating novel T790M/C797S-EGFR tyrosine kinase inhibitors to overcome the problem of mutation and resistance in non small cell lung cancer (NSCLC). Journal of Biomolecular Structure and Dynamics 39:8, pages 2838-2856.
Read now
Read now
Xin Sun, Shan Xu, Zunhua Yang, Pengwu Zheng & Wufu Zhu. (2021) Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014-present). Expert Opinion on Therapeutic Patents 31:3, pages 223-238.
Read now
Read now
Harun M. Patel, Iqrar Ahmad, Rahul Pawara, Matin Shaikh & Sanjay Surana. (2021) In silico search of triple mutant T790M/C797S allosteric inhibitors to conquer acquired resistance problem in non-small cell lung cancer (NSCLC): a combined approach of structure-based virtual screening and molecular dynamics simulation. Journal of Biomolecular Structure and Dynamics 39:4, pages 1491-1505.
Read now
Read now
Harun Patel, Azim Ansari, Rahul Pawara, Iqrar Ansari, Harsha Jadhav & Sanjay Surana. (2018) Design and synthesis of novel 2,4-disubstituted aminopyrimidines: reversible non-covalent T790M EGFR inhibitors. Journal of Receptors and Signal Transduction 38:5-6, pages 393-412.
Read now
Read now
Xiaochun Wang, David Goldstein, Philip J Crowe & Jia-Lin Yang. (2016) Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence. OncoTargets and Therapy 9, pages 5461-5473.
Read now
Read now
Articles from other publishers (14)
Satyam Singh, Revathy Sahadevan, Rajarshi Roy, Mainak Biswas, Priya Ghosh, Parimal Kar, Avinash Sonawane & Sushabhan Sadhukhan. (2022)
Structure-based design and synthesis of a novel long-chain 4′′-alkyl ether derivative of EGCG as potent EGFR inhibitor:
in vitro
and
in silico
studies
. RSC Advances 12:28, pages 17821-17836.
Crossref
Crossref
Long-fei Mao, Zhen-Zhen Wang, Qiong Wu, Xiaojie Chen, Jian-Xue Yang, Xin Wang & Yue-Ming Li. (2022) Design, Synthesis, and Antitumor Activity of Erlotinib Derivatives. Frontiers in Pharmacology 13.
Crossref
Crossref
Hui Liu, Weimin Qiu, Tianyu Sun, Lei Wang, Chenxi Du, Yanyu Hu, Wenyuan Liu, Feng Feng, Yao Chen & Haopeng Sun. (2022) Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds. Acta Pharmaceutica Sinica B 12:4, pages 1781-1804.
Crossref
Crossref
Girish Chandra Arya, Kamalpreet Kaur & Vikas Jaitak. (2021) Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies. European Journal of Medicinal Chemistry 221, pages 113511.
Crossref
Crossref
Harun Patel, Iqrar Ahmad, Harsha Jadhav, Rahul Pawara, Deepak Lokwani & Sanjay Surana. (2021) Investigating the Impact of Different Acrylamide (Electrophilic Warhead) on Osimertinib’s Pharmacological Spectrum by Molecular Mechanic and Quantum Mechanic Approach. Combinatorial Chemistry & High Throughput Screening 25:1, pages 149-166.
Crossref
Crossref
Eman T. Warda, Ihsan A. Shehata, Mahmoud B. El-Ashmawy & Nadia S. El-Gohary. (2020) New series of isoxazole derivatives targeting EGFR-TK: Synthesis, molecular modeling and antitumor evaluation. Bioorganic & Medicinal Chemistry 28:21, pages 115674.
Crossref
Crossref
Ge Yan, Yunfu Wang, Jincao Chen, Wenzhong Zheng, Changzhen Liu, Shi Chen, Lianrong Wang, Jie Luo & Zhiqiang Li. (2020) Advances in drug development for targeted therapies for glioblastoma. Medicinal Research Reviews 40:5, pages 1950-1972.
Crossref
Crossref
Qamar Ghafoor, Shobhit Baijal, Phillipe Taniere, Brendan O’Sullivan, Matthew Evans & Gary Middleton. (2017) Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) – Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy. Pathology & Oncology Research 24:4, pages 723-731.
Crossref
Crossref
Xiaoyun Lu, Lei Yu, Zhang Zhang, Xiaomei Ren, Jeff B. Smaill & Ke Ding. (2018)
Targeting EGFR
L858R/T790M
and EGFR
L858R/T790M/C797S
resistance mutations in NSCLC: Current developments in medicinal chemistry
. Medicinal Research Reviews 38:5, pages 1550-1581.
Crossref
Crossref
Chih-Jen Yang, Jen-Yu Hung, Ming-Ju Tsai, Kuan-Li Wu, Ta-Chih Liu, Shah-Hwa Chou, Jui-Ying Lee, Jui-Sheng Hsu, Ming-Shyan Huang & Inn-Wen Chong. (2017) The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy. BMC Pharmacology and Toxicology 18:1.
Crossref
Crossref
Hongjian Li, Christy Wing-Sum Tong, Yee Leung, Man-Hon Wong, Kenneth Kin-Wah To & Kwong-Sak Leung. (2017) Identification of Clinically Approved Drugs Indacaterol and Canagliflozin for Repurposing to Treat Epidermal Growth Factor Tyrosine Kinase Inhibitor-Resistant Lung Cancer. Frontiers in Oncology 7.
Crossref
Crossref
Ross A. Soo, Emily C.A. Stone, K. Michael Cummings, James R. Jett, John K. Field, Harry J.M. Groen, James L. Mulshine, Yasushi Yatabe, Lukas Bubendorf, Sanja Dacic, Ramon Rami-Porta, Frank C. Detterbeck, Eric Lim, Hisao Asamura, Jessica Donington, Heather A. Wakelee, Yi-Long Wu, Kristin Higgins, Suresh Senan, Benjamin Solomon, Dong-Wan Kim, Melissa Johnson, James C.H. Yang, Lecia V. Sequist, Alice T. Shaw, Myung-Ju Ahn, Daniel B. Costa, Jyoti D. Patel, Leora Horn, Scott Gettinger, Solange Peters, Murry W. Wynes, Corinne Faivre-Finn, Charles M. Rudin, Anne Tsao, Paul Baas, Ronan J. Kelly, Natasha B. Leighl, Giorgio V. Scagliotti, David R. Gandara, Fred R. Hirsch & David R. Spigel. (2017) Scientific Advances in Thoracic Oncology 2016. Journal of Thoracic Oncology 12:8, pages 1183-1209.
Crossref
Crossref
Ming-Ze Qin, Lei Wang, Shuang Yan, Jun-Jie Ma, Ye Tian, Yan-Fang Zhao & Ping Gong. (2017) Identification of hydrazone moiety-bearing aminopyrimidines as potent antitumor agents with selective inhibition of gefitinib-resistant H1975 cancer cells. Chinese Chemical Letters 28:5, pages 991-994.
Crossref
Crossref
Paola Ulivi. (2016) Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?. International Journal of Molecular Sciences 17:7, pages 1186.
Crossref
Crossref